Navigation Links
ChromaDex Announces 2008 Year End Financial Results
Date:4/3/2009

IRVINE, Calif., April 3 /PRNewswire-FirstCall/ -- ChromaDex Corporation, (OTC Bulletin Board: CDXC) a leader in phytochemical reference standards and contract research, today announced financial results for the 2008 Fiscal Year. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.07 per share for the twelve months ended January 3, 2009.

As of January 3, 2009, cash, cash equivalents, and marketable securities totaled $1 million.

"The FDA started implementing Good Manufacturing Practices for dietary supplements in June 2008," said Frank Jaksch, CEO and co-founder of ChromaDex. "There is a rapidly growing awareness both at the consumer and government regulatory level of the need for reference standards, analytical methods and other quality assurance methods to insure that products on the shelf not only contain what is claimed on the label, but are also safe and effective. We are confident that the increased awareness and demand for products that are healthy, natural, organic or green, will continue to provide an opportunity for ChromaDex. Additionally, we will continue to invest in products, services and intellectual property that will enable us to remain the reference standards market leader for the dietary supplement, food, beverage, personal care, and sport nutrition markets."

Additional Financial Results & Notes

On a reported basis, ChromaDex recorded revenue during 2008 of $4,506,301 as compared to $4,754,073 for the same period in 2007. The net loss attributable to common stockholders for the twelve months ended January 3, 2009, was $2,104,476 as compared to a net loss of $189,875 for the same period in 2007. The company notes that as a result of its closing of the reverse merger acquisition of Cody Resources, Inc. on June 20, 2008, investors are cautioned that the company's historical performance is not directly comparable.

About ChromaDex

ChromaDex is a leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Corporation

10005 Muirlands Blvd, Suite G

Irvine, CA 92618

Phone 949-419-0288

Fax 949-419-0294

Email info@chromadex.com

www.chromadex.com

    ChromaDex Corporation and Subsidiaries

    Consolidated Statements of Operations
    Years Ended January 3, 2009 and December 29, 2007

                                                    2008        2007

    Sales                                        $4,506,301  $4,754,073

    Cost of goods sold                            3,274,800   3,122,461

     Gross profit                                 1,231,501   1,631,612

    Operating expenses:
     Selling                                        720,519     387,816
     General and administrative                   2,579,015   1,421,516
                                                  3,299,534   1,809,332

     Operating loss                              (2,068,033)   (177,720)

    Nonoperating (income) expenses:
     Interest expense                                70,079      31,815
     Interest and other income                      (33,636)    (19,660)
                                                     36,443      12,155

     Net loss                                   $(2,104,476)  $(189,875)


    Basic and Diluted loss per common share          $(0.07)     $(0.01)


    Basic and Diluted average common shares
     outstanding                                 28,312,934  26,514,481



'/>"/>
SOURCE ChromaDex Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Announces Second Quarter 2008 Financial Results
2. ChromaDex, Inc. Announces Completion of Reverse Merger With Cody Resources, Inc.
3. China Agri-Business Announces 2008 Operating Results
4. Verenium Announces Organizational Changes
5. ThermoGenesis Announces Abstracts to Be Presented at Upcoming Stem Cell Therapy Conference
6. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
7. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
8. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
9. China Biologic Products Announces Strong 2008 Results
10. Senetek PLC Announces New Investor Communication Hotline
11. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
Breaking Biology Technology:
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):